Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stephanie Pickett

Urogynecology and Reconstructive Pelvic Surgery Edmond, OK Medical Doctor

NPI 1255592952 CMS profile 1318735

2017 W I 35 Frontage Rd, Edmond, OK 73013

Open in the dashboard

General payments

$8,481

319 records reported · program years 2019–2025

Research payments

$788

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stephanie Pickett of Edmond, OK is reported in the CMS Open Payments database as having received $8,481 across 319 general payments and $788 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,346 36
2024 General $715 40
2023 General $1,282 64
2022 General $1,283 63
2022 Research $788 1
2021 General $1,684 70
2020 General $626 22
2019 General $545 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephanie Pickett
  • Urogynecology and Reconstructive Pelvic Surgery median
  • Middle half of Urogynecology and Reconstructive Pelvic Surgery
  • National median

In program year 2025, general payments to Stephanie Pickett were reported at $2,346. Among 802 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $412 and the middle half received between $133 and $1,300.

Show as a table
Year Stephanie Pickett Urogynecology and Reconstructive Pelvic Surgery median Middle half National median
2019 $545 $358 $132–$1,270 $163
2020 $626 $198 $86–$642 $114
2021 $1,684 $361 $118–$1,182 $132
2022 $1,283 $410 $128–$1,175 $149
2023 $1,282 $434 $152–$1,344 $160
2024 $715 $494 $193–$1,331 $164
2025 $2,346 $412 $133–$1,300 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $1,410 8 payments
  2. Medtronic, Inc. $1,269 49 payments
  3. Axonics Modulation Technologies, Inc. $706 11 payments
  4. Coloplast Corp $564 14 payments
  5. AbbVie, Inc. $540 26 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $498 34 payments
  7. Medtronic USA, Inc. $373 6 payments
  8. Astellas Pharma US Inc $366 21 payments
  9. Sumitomo Pharma America, Inc. $366 20 payments
  10. Caldera Medical, Inc $329 23 payments
  11. Other $2,059 107 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,360 306 payments
  2. Travel and Lodging $1,045 8 payments
  3. Education $76 5 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $1,410 8 payments
  2. INTERSTIM Sacral Nerve Stimulation $1,156 43 payments
  3. Axonics $503 5 payments
  4. GEMTESA $481 27 payments
  5. INTERSTIM Sacral Nerve Stimulation $373 6 payments
  6. Desara $309 22 payments
  7. Altis Women's Health $296 7 payments
  8. MYRBETRIQ $293 17 payments
  9. XIFAXAN $262 16 payments
  10. ALTIS Female Incontinence $249 6 payments
  11. Other $3,416 190 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $788 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

2,133

Median for Obstetrics & Gynecology: 65

Drug cost

$747,419

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

55.6%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 499 $375,441
Gemtesa Vibegron Brand 254 $194,494
Premarin Estrogens, Conjugated Brand 124 $54,993
Linzess Linaclotide Brand 51 $41,981
Estradiol Generic 507 $33,438
Estring Estradiol Brand 40 $21,634
Imvexxy Estradiol Brand 36 $11,878
Trospium Chloride Generic 86 $3,836
Methenamine Hippurate Generic 34 $2,269
Colesevelam Hcl Generic 13 $1,947

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 65 billing codes

Paid by Medicare

$165,716

Of which drugs: $7,483

Medicare patients

649

Average age 75

Services billed

3,370

649 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 62%
Osteoporosis 29%
Chronic kidney disease 28%
Ischemic heart disease 27%
Depression 25%
Diabetes 23%
Cancer 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 15 1,500 $7,483

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GEMTESA
  • Sumitomo Pharma America, Inc. $110
$110 254 —
Veozah
  • Astellas Pharma US Inc $38
$38 — —
SLYND
  • Exeltis, USA Inc. $17
$17 — —
TRULANCE
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $15
$15 — —
ABRYSVO
  • PFIZER INC. $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

320 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urogynecology and Reconstructive Pelvic Surgery in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record